Patients and Methods We evaluated tumor cell expression of VEGF, VEGF receptor (VEGFR) 1, and VEGFR2 using automatic immunostaining in a series of 298 patients with early-stage NSCLC recruited as part ...
Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.
The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...
*all partial responses; ** intention to treat population. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text component.
Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...
CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results